Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

OBJECTIVE--To determine whether epoprostenol (prostacyclin, PGI2) or heart-lung transplantation (HLT), or both improves survival of patients with severe pulmonary hypertension. DESIGN--This was a prospective study where the effects of epoprostenol were compared with conventional treatment. Also, the...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British Heart Journal Ročník 70; číslo 4; s. 366 - 370
Hlavní autori:	Higenbottam, T W, Spiegelhalter, D, Scott, J P, Fuster, V, Dinh-Xuan, A T, Caine, N, Wallwork, J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BMJ Publishing Group Ltd and British Cardiovascular Society 01.10.1993 BMJ BMJ Publishing Group LTD
Predmet:	Adult Biological and medical sciences Cardiovascular system Combined Modality Therapy Epoprostenol - therapeutic use Female Heart-Lung Transplantation Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - mortality Hypertension, Pulmonary - surgery Hypertension, Pulmonary - therapy Male Medical sciences Pharmacology. Drug treatments Prospective Studies Survival Rate Vasodilator agents. Cerebral vasodilators Heart Human Vasodilator agent Prostaglandin I2 Respiratory disease Treatment efficiency Lung Cardiovascular disease Transplantation Homotransplantation Pulmonary hypertension Chemotherapy Treatment Surgery Comparative study
ISSN:	0007-0769, 1468-201X, 2053-5864
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!